Carboplatin



Essential medicine status 🗸

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

	ATC codes: L01XA02
Indication	Malignant neoplasms of breast ICD11 code: 2D2Z
INN	Carboplatin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
EML status history	First added in 2009 (TRS 958) Changed in 2015 (TRS 994)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Carboplatin
DrugBank	Carboplatin 🗹

Summary of evidence and Expert Committee recommendations

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML for use in treatment protocols for early stage breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for early stage breast cancer is attached.

Expert Committee report \, 🔊

